Breakpoint position on 17q identifies the most aggressive neuroblastoma tumors

Genes Chromosomes and Cancer

Volumn 34, Issue 4, 2002, Pages 428-436

  Łastowska, Maria ^a,d   Cotterill, Simon ^a   Bown, Nick ^a   Cullinane, Catherine ^b   Variend, Sadick ^c   Lunec, John ^a   Strachan, Tom ^a   Pearson, Andrew D J ^a   Jackson, Michael S ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^d INSTITUTE OF HUMAN GENETICS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER SURVIVAL; CHROMOSOME 17; CHROMOSOME ABERRATION; CHROMOSOME MAP; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; GENE LOCATION; GENE MAPPING; GENE PROBE; HUMAN; HUMAN TISSUE; MITOSIS INDEX; NEUROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH;

CHROMOSOME BREAKAGE; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 17; GENES, ERBB-2; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEUROBLASTOMA; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0036076036     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.10089     Document Type: Article

References (42)

1. Cytogenetic abnormalities of small round cell tumours
2. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma
3. Comparative genomic hybridization (CGH) analysis of neuroblastomas: An important methodological approach in paediatric tumor pathology
4. Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma
5. Recurrent 1:17 translocations in human neuroblastoma reveal nonhomologous mitotic recombination during the S/G2 phase as a novel mechanism for loss of heterozygosity
6. Relative prognostic value of genetic factors in neuroblastoma
7. Tumour karyotype discriminates between good and bad prognostic outcome in neuroblastoma
8. Clinical prognostic factors in 1277 patients with neuroblastoma: Results of The European Neuroblastoma Study Group "Survey" 1982-1992
9. Localization of PS6K to chromosomal region 17q23 and determination of its amplification in breast cancer
10. Nm23/nucleoside diphosphate kinase: Towards a structural and biochemical understanding of its biological functions
11. Successful management of low-stage neuroblastoma without adjuvant therapies: A comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution
12. Genome screening by comparative genomic hybridization
13. Comparative genomic hybridisation analysis of 38 breast cancer cell lines: A basis for interpreting complementary DNA microarray data
14. High levels of p19/nm23 protein in neuroblastoma are associated with advanced stage disease and with N-myc gene amplification
15. Chromosome findings and prognosis in neuroblastoma
16. Genetic aberrations detected by comparative genomic hybridisation predict outcome in nodenegative breast cancer
17. Molecular analysis of chromosome arm 17q gain in neuroblastoma
18. Nonparametric estimation from incomplete observations
19. Online access to CGH data of DNA sequence copy number changes
20. Comparative genomic hybridisation of malignant fibrous histiocytoma reveals a novel prognostic marker
21. Comparative genomic hybridization study of primary neuroblastoma tumors
22. Gain of chromosome arm 17q predicts unfavorable outcome in neuroblastoma patients
23. Molecular cytogenctic delineation of 17q translocation breakpoints in neuroblastoma cell lines
24. Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumours
25. Evidence for nm23 RNA overexpression. DNA amplification and mutation in aggressive childhood neuroblastomas
26. Cellular DNA content as predictor of response to chemotherapy in infants with unresectable neuroblastoma
27. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: A Children's Cancer Group study
28. Additional copies of a 25 Mb chromosomal region originating from 17q23.1-17qter are present in 90% of high-grade neuroblastomas
29. Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer
30. Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization
31. Translocation involving 1p and 17q is a recurrent genetic alteration of human neuroblastoma cells
32. Genomic imbalances of 7p and 17q in malignant peripheral nerve sheat tumours are clinically relevant
33. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage
34. Terminology and morphologic criteria of neuroblastic tumours
35. The International Neuroblastoma Pathology Classification (the Shimada system)
36. An increased NM23H1 copy number may be a poor prognostic factor independent of LOH on 1p in neuroblastomas
37. DNA sequence copy number increase at 8q: A potential new prognostic marker in high-grade osteosarcoma
38. Clinical correlation of genetic changes in Ewing sarcoma and related tumours
39. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations
40. Molecular cytogenetic analysis of 1;17 translocations in neuroblastoma
41. Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: Toward a genetic model of meningioma progression
42. 17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and SIGMA1B genes